Takeda Pharmaceutical Co Ltd
TAK17.470USD
-0.020-0.11%
Fechamento 02/02, 16:00（ET）Cotações atrasadas em 15 min
55.19BValor de mercado
76.06P/L TTM
Mais detalhes de Takeda Pharmaceutical Co Ltd Empresa
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Informações de Takeda Pharmaceutical Co Ltd
Código da empresaTAK
Nome da EmpresaTakeda Pharmaceutical Co Ltd
Data de listagemJun 21, 2085
CEOWeber (Christophe)
Número de funcionários47455
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 21
Endereço4F
CidadeCHUO-KU
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísJapan
Código postal103-8668
Telefone81332782111
Sitehttps://www.takeda.com/
Código da empresaTAK
Data de listagemJun 21, 2085
CEOWeber (Christophe)
Executivos da empresa Takeda Pharmaceutical Co Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
Outro
72.06B
6.48%
Por RegiãoUSD
Nome
Receita
Proporção
United States
545.17B
48.99%
Europe And Canada (Country)
272.90B
24.52%
Japan
111.06B
9.98%
Latin America
60.92B
5.47%
China (Country)
49.45B
4.44%
Outro
73.28B
6.59%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
Outro
72.06B
6.48%
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
Outro
99.00%
Investidores
Investidores
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
Outro
99.00%
Tipos de investidores
Investidores
Proporção
Investment Advisor
1.79%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.32%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Outro
97.31%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
610
83.80M
2.65%
-4.87M
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital Research Global Investors
13.40M
0.42%
+108.56K
+0.82%
Sep 30, 2025
Parametric Portfolio Associates LLC
6.05M
0.19%
+74.59K
+1.25%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.17M
0.13%
+85.28K
+2.09%
Sep 30, 2025
UBS Financial Services, Inc.
5.86M
0.19%
+1.88M
+47.19%
Sep 30, 2025
Brandes Investment Partners, L.P.
3.93M
0.12%
+219.53K
+5.91%
Sep 30, 2025
Renaissance Technologies LLC
3.86M
0.12%
+565.40K
+17.14%
Sep 30, 2025
Goldman Sachs Asset Management, L.P.
3.33M
0.11%
+481.85K
+16.91%
Sep 30, 2025
Aperio Group, LLC
3.31M
0.1%
+100.83K
+3.15%
Sep 30, 2025
TD Securities, Inc.
3.00M
0.1%
+3.00M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
2.83M
0.09%
+1.61M
+132.12%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
Ver Mais
VanEck Pharmaceutical ETF
Proporção5.05%
SGI Enhanced Global Income ETF
Proporção0.76%
Adasina Social Justice All Cap Global ETF
Proporção0.49%
First Trust Value Line Dividend Index Fund
Proporção0.38%
ActivePassive International Equity ETF
Proporção0.3%
Avantis Responsible International Equity ETF
Proporção0.09%
Avantis International Equity ETF
Proporção0.05%
Roundhill GLP-1 & Weight Loss ETF
Proporção0%
DFA Dimensional International Core Equity 2 ETF
Proporção0%
Invesco Zacks Multi-Asset Income ETF
Proporção0%
Dividendo
Um total de
1.44T
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
